BC Cancer - Vancouver

600 W 10th Avenue
Vancouver, BC V5Z 4E6

Clinical Trial Unit Manager
Darko Curman
604-877-6000 x673226
dcurman@bccancer.bc.ca

Kidney

CheckMate 914: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Cancer Type
Kidney
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

PIVOT IO 011: A Phase 1/2 Study to Compare Bempegaldesleukin Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) 

An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC)

Back to top